M31 Collaborates with TSMC to Advance 2nm eUSB2 IP Innovation
HSINCHU,
Reinforcing its robustness and reliability on advanced nodes, M31's eUSB2 IP solutions have been widely adopted by leading global companies in high-end smartphone chipsets and AI-driven image processing applications. Building on this success, M31 is currently advancing the development of eUSB2V2 IP on TSMC's N3 and N2 process technologies - expanding its comprehensive eUSB2 portfolio to include eUSB2 V1, V2 PHY, and eUSB2 Repeater solutions. Leveraging the eUSB2 standard, eUSB2V2 enhances data transfer rates while maintaining a low-voltage interface and leveraging asymmetric bandwidth technology—allowing TX and RX to operate at different data rates. This significantly improves transmission efficiency, making it ideal for embedded applications such as AI edge computing, smart surveillance, and image processing chips. To accommodate diverse design needs, eUSB2V2 leverages and enhances the I/O architecture based on the eUSB2 standard, supporting data transfer speeds from 480 Mbps up to 4.8 Gbps. The solution delivers a comprehensive eUSB2 platform for high-end SoCs—optimizing power efficiency, performance and design flexibility, while maintaining full compatibility with legacy USB 2.0 devices.
At the 2025 TSMC North America Technology Symposium,
"We are pleased to collaborate with M31 in driving IP advancements to enable future products," said Lipen Yuan, Senior Director of Advanced Technology Business Development at TSMC. "We look forward to strengthening our collaboration with OIP partners like M31 by joining forces to fuel innovation in next-generation AI and high-performance computing applications with TSMC's industry-leading process technologies."
View original content to download multimedia:https://www.prnewswire.com/news-releases/m31-collaborates-with-tsmc-to-advance-2nm-eusb2-ip-innovation-302437210.html
SOURCE M31 Technology Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PECHOIN Marks Its 10th Year at IFSCC, Showcasing Advances in Asian Skin Research
- RIMAN Expands Global Footprint to 22 Markets with Launches Across Europe and Latin America
- Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share